<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168997</url>
  </required_header>
  <id_info>
    <org_study_id>17237T</org_study_id>
    <nct_id>NCT03168997</nct_id>
  </id_info>
  <brief_title>Memantine Treatment in Alzheimer's Disease Patients</brief_title>
  <official_title>Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Cuibai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether there will be any efficacy difference of&#xD;
      Memantine treatment in different cognitive severity AD patients stratified with BPSD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Planed to enroll a total of 222 patients with mild, moderate or severe AD treated with&#xD;
      Memantine in 2017-2018 from 15 centers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-cog change</measure>
    <time_frame>ADAD-cog Change from baseline to 24 weeks</time_frame>
    <description>Alzheimer's Disease Co-operative Study Alzheimer's Disease Assessment Scale - cognitive section is the cognitive evaluation scale</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Mild AD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Memantine Hydrochloride 20mg tablet per day by mouth on mild AD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate AD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe AD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Memantine Hydrochloride 20mg tablet per day by mouth on severe AD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride</intervention_name>
    <description>Memantine Hydrochloride treatment according to clinical routine treatment</description>
    <arm_group_label>Mild AD</arm_group_label>
    <arm_group_label>Moderate AD</arm_group_label>
    <arm_group_label>Severe AD</arm_group_label>
    <other_name>Memantine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Probable AD based on the diagnosis criteria of NIA-AA guideline (the U.S. National&#xD;
             Institute on Aging and Alzheimer's Association guideline, McKhann et al, 2011[8];&#xD;
&#xD;
          2. Male or female, 50 years and older ;&#xD;
&#xD;
          3. All inpatients or outpatients recruited into this study must meet MMSE score â‰¤24&#xD;
             points, patients with MMSE score as 21-24 points will be enrolled into mild group,&#xD;
             patients with MMSE score as 10-20 points will be enrolled into moderate group,&#xD;
             patients with MMSE score less than 10 points will be enrolled into severe group.&#xD;
&#xD;
          4. Have a reliable caregiver who can accompany the patient to the site to complete the&#xD;
             required study procedures;&#xD;
&#xD;
          5. Provide the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with disturbance of consciousness of any causes;&#xD;
&#xD;
          2. Patients with severe aphasia or physical disability who were unable to complete&#xD;
             neuropsychological examination;&#xD;
&#xD;
          3. Patients with mental illness;&#xD;
&#xD;
          4. Patients with a history of alcoholism and drug addiction, or traumatic brain injury,&#xD;
             epilepsy, encephalitis, normal-pressure hydrocephalus and other neurological disorders&#xD;
             causing cognitive impairment;&#xD;
&#xD;
          5. Patients with systemic diseases causing dementia (e.g. liver and kidney insufficiency,&#xD;
             endocrine disorders, vitamin deficiency);&#xD;
&#xD;
          6. Patients with a history of ischemic or hemorrhagic cerebrovascular diseases, and&#xD;
             vascular diseases (stroke foci) as confirmed by imaging examination;&#xD;
&#xD;
          7. Subjects who are unwilling or unable to abide by the study requirement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Wei Cuibai</investigator_full_name>
    <investigator_title>Professor, MD, PhD.</investigator_title>
  </responsible_party>
  <keyword>Alzheimer Disease Memantine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

